Thrivent Financial for Lutherans lifted its stake in LeMaitre Vascular Inc (NASDAQ:LMAT) by 5.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,738 shares of the medical instruments supplier’s stock after acquiring an additional 685 shares during the quarter. Thrivent Financial for Lutherans’ holdings in LeMaitre Vascular were worth $342,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in the stock. Swiss National Bank grew its stake in LeMaitre Vascular by 4.2% in the fourth quarter. Swiss National Bank now owns 32,300 shares of the medical instruments supplier’s stock valued at $1,161,000 after purchasing an additional 1,300 shares in the last quarter. State Street Corp raised its position in LeMaitre Vascular by 6.3% during the fourth quarter. State Street Corp now owns 656,359 shares of the medical instruments supplier’s stock valued at $23,596,000 after acquiring an additional 39,113 shares in the last quarter. Victory Capital Management Inc. lifted its stake in LeMaitre Vascular by 165.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,767 shares of the medical instruments supplier’s stock valued at $711,000 after acquiring an additional 12,313 shares during the last quarter. PNC Financial Services Group Inc. grew its position in LeMaitre Vascular by 952.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,653 shares of the medical instruments supplier’s stock worth $203,000 after acquiring an additional 5,116 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of LeMaitre Vascular by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 101,715 shares of the medical instruments supplier’s stock worth $3,657,000 after purchasing an additional 2,963 shares during the last quarter. Institutional investors and hedge funds own 83.76% of the company’s stock.
Shares of NASDAQ LMAT opened at $26.40 on Wednesday. The business’s 50 day moving average is $25.62 and its two-hundred day moving average is $29.32. The company has a market cap of $524.08 million, a P/E ratio of 30.34, a P/E/G ratio of 5.77 and a beta of 1.32. LeMaitre Vascular Inc has a 12 month low of $18.76 and a 12 month high of $38.64.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $30.55 million during the quarter, compared to analysts’ expectations of $30.50 million. LeMaitre Vascular had a return on equity of 12.26% and a net margin of 14.75%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.17 EPS. Sell-side analysts expect that LeMaitre Vascular Inc will post 0.42 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.095 per share. This represents a $0.38 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date of this dividend was Tuesday, May 19th. LeMaitre Vascular’s dividend payout ratio is 43.18%.
A number of equities research analysts recently issued reports on LMAT shares. Stifel Nicolaus decreased their price objective on shares of LeMaitre Vascular from $30.00 to $25.00 and set a “hold” rating for the company in a report on Monday, May 4th. Barrington Research decreased their price target on LeMaitre Vascular from $38.00 to $32.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Sidoti cut their price objective on LeMaitre Vascular from $38.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $28.00 price target on shares of LeMaitre Vascular in a report on Tuesday, June 23rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $31.00.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.